No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MNMD240621C7000
- 0.35
- -0.23-39.66%
15min DelayTrading Jun 20 13:35 ET
0.44High0.35Low
0.43Open0.58Pre Close5 Volume196 Open Interest7.00Strike Price208.00Turnover145.09%IV1.24%PremiumJun 21, 2024Expiry Date0.26Intrinsic Value100Multiplier1DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type0.7012Delta0.5170Gamma18.15Leverage Ratio-0.0944Theta0.0002Rho12.73Eff Leverage0.0016Vega
Intraday
- 5D
- Daily
News
Express News | MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Leerink Partners Maintains Mind Medicine(MNMD.US) With Buy Rating
Leerink Partners analyst Rudy Li maintains $Mind Medicine(MNMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.8% and a total average return of 11.2% over the p
Baird Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $27
Baird analyst Joel Beatty maintains $Mind Medicine(MNMD.US)$ with a buy rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 46.7% and a total av
Don't Freak Out. It Isn't the End of the Line for Psychedelic Medicines. -- Barrons.com
By Josh Nathan-Kazis Turn on, tune in, drop in value. A frigid reception for one novel psychedelic treatment by a Food and Drug Administration advisory committee doesn't spell doom for all psychedel
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outwe
Comments
$Mind Medicine(MNMD.US$ MindMed Reports Completion Of End-of-phase 2 Meeting With FDA; Says Reached Alignment On Phase 3 Development Strategy For MM120 In Generalized Anxiety Disorder
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
Benzinga· 2 mins ago
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this ...
1
$Seelos Therapeutics(SEEL.US$ $Cybin(CYBN.US$ $Mind Medicine(MNMD.US$ FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
A panel of advisors to the U.S. FDA declined to endorse Lykos Therapeutics' application to market to psychedelic drug MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder.
The Psychopharmacologic Drugs Advisory Committee held votes on twoquestions. The first dealt was the drug's efficacy in PTSD, while the second aske...
5
13
$Mind Medicine(MNMD.US$ i swear my brokerage (not moomoo) knows what stocks i buy and instantly shorts my stock
1
2
$Mind Medicine (MNMD.US)$ all work force buisness owner operators should invest into this companies products. this could not only benifit people with the disorders outlined in their descriptions but think about our work force in general I know for the agency I work for we have call ins all the time and generally speaking it's almost always the same people it isn't just my agency but national, jobs every wherewould benifit. so this company could help everyone every where! This company will ris...
1
Read more